Novartis signs up to $7.8 billion mRNA licensing deal with China's Abogen
Novartis and Chinese biotech firm Abogen have entered a licensing agreement for the mRNA drug candidate ABO2203. The deal is valued at up to $7.8 billion, comprising a $575 million upfront payment and up to $7.2 billion in milestone payments. Novartis receives worldwide exclusive rights and options on additional RNA‑based therapies. The agreement was announced on 2 October 2026.
Why it matters
The transaction adds a new pipeline asset and offers substantial upside payments, which could improve Novartis' growth outlook. Gillian Hollenstein of Point Capital Navigator Fund said the deal has a better risk profile because of the smaller upfront amount. Investors may view the deal as a positive step toward diversifying Novartis' portfolio.
Key facts
- 1The licensing agreement is valued at up to $7.8 billion. marketscreener.com
- 2Novartis will pay $575 million upfront. morningstar.com
- 3Additional payments could total up to $7.2 billion if milestones are met. morningstar.com
- 4Novartis obtains worldwide exclusive rights to the experimental drug ABO2203. morningstar.com
- 5ABO2203 is an mRNA therapy targeting B cells for autoimmune diseases such as lupus and rheumatoid arthritis. marketscreener.com
- 6The deal was announced on 2 October 2026. marketscreener.com
Summary written by AlphAI from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.